Expansion opportunities With recent product launches like the Exradin A30 and QA BeamChecker Pro plus a broad hardware and software portfolio, Standard Imaging is expanding its QA solutions footprint in radiation therapy. This creates upsell and cross-sell opportunities for clinics upgrading equipment, adopting newer QA methods, or consolidating QA tools under integrated solutions.

Clinical adoption momentum Active participation in major industry events (ASTRO, AAPM, ESTRO) and timely product introductions indicate strong market engagement and adoption momentum. Sales teams can leverage event activity to target attendees from clinics planning upcoming capital purchases or QA upgrades.

Innovative product pipeline A patent-pending thin parallel plate Exradin A30 and 6DoF head adjustment with TruPose point to a focus on precision accuracy and advanced biomechanics in QA. This suggests opportunities to position around high-accuracy QA for emerging treatment modalities and ultra-high dose rate therapies.

Global partner positioning The company emphasizes partnerships, reliability, and worldwide customer care. This positions Standard Imaging well for multi-site hospital networks and international clinics seeking vendor stability, robust support, and integrated QA solutions across campuses.

Mid-market growth fit Estimated revenue in the 10–25 million range and a staff size of 51–200 indicate strong mid-market presence. There is potential to pursue mid-sized clinics and regional health systems seeking scalable QA solutions with comprehensive service and ongoing innovation.